Inclusion Criteria:
• Eastern Cooperative Oncology Group Performance Status of 0 to 2
For Parts A & B:
- Relapsed or refractory (R/R) acute myeloid leukemia (AML) as defined by the 2016 WHO
Classification
- R/R myelodysplastic syndromes (MDS) as defined by the 2016 WHO Classification with
intermediate, high or very high risk by Revised International Prognostic Scoring
System (IPSS-R)
For Part C:
• Treatment-naïve (TN) (ie, previously untreated) MDS as defined by the 2016 WHO
Classification with intermediate, high or very high risk by IPSS-R
For Part D:
• TN AML as defined by the 2016 WHO Classification, including secondary AML and
therapy-related AML in participants who are ineligible (IE) for intensive chemotherapy (IC)
and allogeneic hematopoietic stem cell transplant (HSCT)
Exclusion Criteria:
- Acute promyelocytic leukemia
- Immediately life-threatening, severe complications of leukemia such as
disseminated/uncontrolled infection, uncontrolled bleeding, and/or uncontrolled
disseminated intravascular coagulation
- Participants who have received prior treatment with a CD47 or SIRPα targeting agent
- Participant is on chronic systemic immunosuppressive therapy or corticosteroids
- Prior systemic cancer-directed treatments or investigational modalities ≤ 5 half-lives
or 4 weeks prior to starting study treatment, whichever is shorter (relapsed or
refractory participants only).
- Any condition including, active or uncontrolled infection, or the presence of
laboratory abnormalities, which places the participant at unacceptable risk if he/she
were to participate in the study
- Pregnant or nursing participants.
Other protocol-defined inclusion/exclusion criteria apply
Active, Not Recruiting
